Información del artículo
La candidiasis invasiva se ha convertido en un problema de salud pública debido a las altas tasas de morbimortalidad asociadas. Al igual que otras infecciones sistémicas, es esencial realizar un diagnóstico lo más certero y precoz posible. A pesar de su escasa sensibilidad (50%), el hemocultivo sigue siendo la mejor técnica para el diagnóstico de la candidemia. Para aumentar el rendimiento diagnóstico se han comercializado nuevas técnicas independientes del cultivo, entre las que destacan la detección de anticuerpos antimicelio y la de antígeno (1-3)-β-D-glucano. La combinación de 2 técnicas que detecten antígeno, anticuerpos, (1-3)-β-D-glucano o ADN parece ser la mejor alternativa para optimizar el diagnóstico de la candidiasis invasiva. El fluconazol y, en ocasiones, la anfotericina B, continúan siendo los antifúngicos de elección para el tratamiento de las candidiasis. En los últimos años se han introducido nuevos antifúngicos con el objetivo de mejorar el pronóstico de algunas formas clínicas de esta enfermedad. Las equinocandinas y los triazoles de segunda generación tienen una actividad antifúngica superior al fluconazol, y en los ensayos clínicos de candidiasis de diferentes localizaciones han mostrado un excelente perfil de eficacia y seguridad. Las posibles interacciones medicamentosas de alguno de estos compuestos son relevantes. La aportación de los nuevos antifúngicos para la terapéutica de las candidiasis se ha de definir en los próximos años.
Palabras clave:
Candidiasis
Anticuerpos antimicelio
(1-3)-β-D-glucano
Equinocandinas
Triazoles
Invasive candidiasis has become a public health problem due to the high associated rates of morbidity and mortality. As in other systemic infections, accurate and early diagnosis is essential. Despite its limited sensitivity (50%), blood culture continues to be the most effective technique for the diagnosis of candidemia.
New culture-independent techniques have been marketed with the aim of improving diagnostic yield. Among these techniques, the most notable are (1-3)-β-D-glucan and anti-germ-tube antibody detection. However, the best option to optimize the diagnosis of invasive candidiasis seems to be the combination of two techniques that detect antigen, antibodies, (1-3)-β-D-glucan or DNA.
Fluconazole, and sometimes amphotericin B, remain the antifungal agents of choice for the treatment of candidiasis.
In the last few years, new antifungal agents have been introduced with the aim of improving the prognosis of some clinical presentations of this disease. The echinocandins and second-generation triazoles show greater antifungal activity than fluconazole. Moreover, clinical trials of candidiasis in different localizations have shown that these drugs have excellent efficacy and safety profiles. The potential for drug interactions with some of these antifungal agents is considerable. The contribution of the new antifungal drugs in the treatment of candidiasis should be defined in the near future.
Key words:
Candidiasis
Anti germ-tube antibodies
(1-3)-β-D-glucan
Echinocandins
Second-generation triazoles
El Texto completo está disponible en PDF
Bibliografía
[1.]
M.A. Pfaller, D.J. Diekema.
Epidemiology of invasive candidiasis: a persistent public health problem.
Clin Microbiol Rev, 20 (2007), pp. 133-163
[2.]
M.B. Edmond, S.E. Wallace, D.K. McClish, M.A. Pfaller, R.N. Jones, R.P. Wenzel.
Nosocomial bloodstream infections in United States hospitals: a three-year analysis.
Clin Infect Dis, 29 (1999), pp. 239-244
[3.]
O. Gudlaugsson, S. Gillespie, K. Lee, B.J. Vande, J. Hu, S. Messer, et al.
Attributable mortality of nosocomial candidemia, revisited.
Clin Infect Dis, 37 (2003), pp. 1172-1177
[4.]
A.M. Rentz, M.T. Halpern, R. Bowden.
The impact of candidemia on length of hospital stay, outcome, and overall cost of illness.
Clin Infect Dis, 27 (1998), pp. 781-788
[5.]
J. Llovo, J. Ponton.
Diagnóstico microscópico de las micosis.
Guía práctica de identificación y diagnóstico en micología clínica,
[6.]
J. Pemán, P. Ramos, I. Iglesias.
Procesamiento de las muestras de sangre, líquidos estériles y tejidos.
Guía práctica de identificación y diagnóstico en micología clínica, pp. 6.1-6.8
[7.]
M.J. Linares, F. Solis.
Identificación de levaduras.
Guía práctica de identificación y diagnóstico en micología clínica, pp. 11.20
[8.]
J. Pemán, N. Aparisi, C. García-Esteban, M. Gobernado.
Rapid identification of Candida glabrata using a new commercial kit.
Rev Iberoam Micol, 21 (2004), pp. 82-84
[9.]
J. Ponton, M.E. García, R. López-Medrano.
Diagnóstico serológico de las micosis.
Guía práctica de identificación y diagnóstico en micología clínica,
[10.]
J. Ponton.
Microbiological non-culture methods for the diagnosis of invasive candidiasis: usefulness of surrogate markers.
Rev Iberoam Micol, 23 (2006), pp. 20-25
[11.]
M.D. Moragues, N. Ortiz, J.R. Iruretagoyena, J.C. García-Ruiz, E. Amutio, A. Rojas, et al.
Evaluation of a new commercial test (Candida albicans IFA IgG) for the serodiagnosis of invasive candidiasis.
Enferm Infecc Microbiol Clin, 22 (2004), pp. 83-88
[12.]
Z. Odabasi, G. Mattiuzzi, E. Estey, H. Kantarjian, F. Saeki, R.J. Ridge, et al.
Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome.
Clin Infect Dis, 39 (2004), pp. 199-205
[13.]
L. Ostrosky-Zeichner, B.D. Alexander, D.H. Kett, J. Vázquez, P.G. Pappas, F. Saeki, et al.
Multicenter clinical evaluation of the (1→3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans.
Clin Infect Dis, 41 (2005), pp. 654-659
[14.]
J.W. Pickering, H.W. Sant, C.A. Bowles, W.L. Roberts, G.L. Woods.
Evaluation of a (1→3)-beta-D-glucan assay for diagnosis of invasive fungal infections.
J Clin Microbiol, 43 (2005), pp. 5957-5962
[15.]
B. Sendid, T. Jouault, R. Coudriau, D. Camus, F. Odds, M. Tabouret, et al.
Increased sensitivity of mannanemia detection tests by joint detection of alpha-and beta-linked oligomannosides during experimental and human systemic candidiasis.
J Clin Microbiol, 42 (2004), pp. 164-171
[16.]
S. Bretagne, J.M. Costa.
Towards a molecular diagnosis of invasive aspergillosis and disseminated candidosis.
FEMS Immunol Med Microbiol, 45 (2005), pp. 361-368
[17.]
M.F. Colom, A. Jover, C. Ferrer.
Molecular biology in the diagnosis of deep-seated candidiasis in the critically ill non-neutropenic patient.
Rev Iberoam Micol, 23 (2006), pp. 26-28
[18.]
C. Pazos, M.D. Moragues, G. Quindos, J. Ponton, A. del Palacio.
Diagnostic potential of (1,3)-beta-D-glucan and anti-Candida albicans germ tube antibodies for the diagnosis and therapeutic monitoring of invasive candidiasis in neutropenic adult patients.
Rev Iberoam Micol, 23 (2006), pp. 209-215
[19.]
P.L. White, A.E. Archer, R.A. Barnes.
Comparison of non-culture-based methods for detection of systemic fungal infections, with an emphasis on invasive Candida infections.
J Clin Microbiol, 43 (2005), pp. 2181-2187
[20.]
R. Kim, D. Khachikian, A.C. Reboli.
A comparative evaluation of properties and clinical efficacy of the echinocandins.
Expert Opin Pharmacother, 8 (2007), pp. 1479-1492
[21.]
C. Wagner, W. Graninger, E. Presterl, C. Joukhadar.
The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications.
Pharmacology, 78 (2006), pp. 161-177
[22.]
G. Eschenauer, D.D. Depestel, P.L. Carver.
Comparison of echinocandin antifungals.
Ther Clin Risk Manag, 3 (2007), pp. 71-97
[23.]
D.W. Denning.
Echinocandin antifungal drugs.
Lancet, 362 (2003), pp. 1142-1151
[24.]
R.H. Raasch.
Anidulafungin: review of a new echinocandin antifungal agent.
Expert Rev Anti Infect Ther, 2 (2004), pp. 499-508
[25.]
J.A. Vázquez, J.D. Sobel.
Anidulafungin: a novel echinocandin.
Clin Infect Dis, 43 (2006), pp. 215-222
[26.]
T.J. Walsh, P.C. Adamson, N.L. Seibel, P.M. Flynn, M.N. Neely, C. Schwartz, et al.
Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents.
Antimicrob Agents Chemother, 49 (2005), pp. 4536-4545
[27.]
C.M. Odio, L.E. Pinto, B. Alfaro, S. Vasquez, C.E. Castro, et al.
Pharmacokinetics (PK) of caspofungin (CAS) in six premature neonates (PNN) with invasive candidiasis (IC) at a neonatal intensive care unit (NNICU).
45th Interscience Conference on Antimicrobial Agents and Chemotherapy (abstract LB-16),
[28.]
N.L. Seibel, C. Schwartz, A. Arrieta, P. Flynn, A. Shad, E. Albano, et al.
Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients.
Antimicrob Agents Chemother, 49 (2005), pp. 3317-3324
[29.]
D.K. Benjamin Jr., T. Driscoll, N.L. Seibel, C.E. González, M.M. Roden, R. Kilaru, et al.
Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections.
Antimicrob Agents Chemother, 50 (2006), pp. 632-638
[30.]
A. Louie, M. Deziel, W. Liu, M.F. Drusano, T. Gumbo, G.L. Drusano.
Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity.
Antimicrob Agents Chemother, 49 (2005), pp. 5058-5068
[31.]
D. Andes.
Pharmacokinetics and pharmacodynamics of antifungals.
Infect Dis Clin North Am, 20 (2006), pp. 679-697
[32.]
J.A. Stone, E.M. Migoya, L. Hickey, G.A. Winchell, P.J. Deutsch, K. Ghosh, et al.
Potential for interactions between caspofungin and nelfinavir or rifampin.
Antimicrob Agents Chemother, 48 (2004), pp. 4306-4314
[33.]
M.F. Hebert, D.K. Blough, R.W. Townsend, M. Allison, D. Buell, J. Keirns, et al.
Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers.
J Clin Pharmacol, 45 (2005), pp. 1018-1024
[34.]
D.S. Krause, A.E. Simjee, C. van Rensburg, J. Viljoen, T.J. Walsh, B.P. Goldstein, et al.
A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis.
Clin Infect Dis, 39 (2004), pp. 770-775
[35.]
V. Petraitis, R. Petraitiene, R.J. Legit.
Combination antifungal therapy with FK463 plus amphotericin B in treatment of experimental pulmonary aspergillosis.
39th Interscience Conference on Antimicrobial Agents and Chemotherapy (abstract 2003),
[36.]
K. Kelley, C. Chapman, J. Cleary.
Digestion of Echinocandins.
46th Interscience Conference on Antimicrobial Agents and Chemotherapy (abstract M-366),
[37.]
N. Kartsonis, M.J. DiNubile, K. Bartizal, P.S. Hicks, D. Ryan, C.A. Sable.
Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole.
J Acquir Immune Defic Syndr, 31 (2002), pp. 183-187
[38.]
J.A. Vázquez, J. Schranz, D. Krause, B.P. Goldstein, A. Reboli, J.L. Hernández, et al.
Efficacy of anidulafungin in patients with azole-refractory mucosal candidiasis (ARMC).
44th Interscience Conference on Antimicrobial Agents and Chemotherapy (abstract M-1038),
[39.]
S.K. Fridkin.
Candidemia is costly—plain and simple.
Clin Infect Dis, 41 (2005), pp. 1240-1241
[40.]
J. Mora-Duarte, R. Betts, C. Rotstein, A.L. Colombo, L. Thompson-Moya, J. Smietana, et al.
Comparison of caspofungin and amphotericin B for invasive candidiasis.
N Engl J Med, 347 (2002), pp. 2020-2029
[41.]
E.R. Kuse, P. Chetchotisakd, C.A. da Cunha, M. Ruhnke, C. Barrios, D. Raghunadharao, et al.
Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial.
Lancet, 369 (2007), pp. 1519-1527
[42.]
P.G. Pappas, C.M. Rotstein, R.F. Betts, M. Nucci, D. Talwar, J.J. De Waele, et al.
Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.
Clin Infect Dis, 45 (2007), pp. 883-893
[43.]
P.G. Pappas.
Invasive candidiasis.
Infect Dis Clin North Am, 20 (2006), pp. 485-506
[44.]
N.A. Kartsonis, A. Saah, C.J. Lipka, A. Taylor, C.A. Sable.
Second-line therapy with caspofungin for mucosal or invasive candidiasis: results from the caspofungin compassionate-use study.
J Antimicrob Chemother, 53 (2004), pp. 878-881
[45.]
L. Ostrosky-Zeichner, D. Kontoyiannis, J. Raffalli, K.M. Mullane, J. Vázquez, E.J. Anaissie, et al.
International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia.
Eur J Clin Microbiol Infect Dis, 24 (2005), pp. 654-661
[46.]
L.J. Scott, D. Simpson.
Voriconazole: a review of its use in the management of invasive fungal infections.
Drugs, 67 (2007), pp. 269-298
[47.]
G. Kofla, M. Ruhnke.
Voriconazole: review of a broad spectrum triazole antifungal agent.
Expert Opin Pharmacother, 6 (2005), pp. 1215-1229
[48.]
T.J. Walsh, M.O. Karlsson, T. Driscoll, A.G. Arguedas, P. Adamson, X. Sáez-Llorens, et al.
Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration.
Antimicrob Agents Chemother, 48 (2004), pp. 2166-2172
[49.]
A.H. Groll, T.J. Walsh.
Posaconazole: clinical pharmacology and potential for management of fungal infections.
Expert Rev Anti Infect Ther, 3 (2005), pp. 467-487
[51.]
G. Krishna, A. Sansone-Parsons, M. Martinho, B. Kantesaria, L. Pedicone.
Posaconazole plasma concentrations in juvenile patients with invasive fungal infection.
Antimicrob Agents Chemother, 51 (2007), pp. 812-818
[52.]
R. Ally, D. Schurmann, W. Kreisel, G. Carosi, K. Aguirrebengoa, B. Dupont, et al.
A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients.
Clin Infect Dis, 33 (2001), pp. 1447-1454
[53.]
B.J. Kullberg, J.D. Sobel, M. Ruhnke, P.G. Pappas, C. Viscoli, J.H. Rex, et al.
Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial.
Lancet, 366 (2005), pp. 1435-1442
[54.]
J.A. Vázquez, D.J. Skiest, L. Nieto, R. Northland, I. Sanne, J. Gogate, et al.
A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS.
Clin Infect Dis, 42 (2006), pp. 1179-1186
[55.]
A.J. Ullmann, J.H. Lipton, D.H. Vesole, P. Chandrasekar, A. Langston, S.R. Tarantolo, et al.
Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.
N Engl J Med, 356 (2007), pp. 335-347
[56.]
O.A. Cornely, J. Maertens, D.J. Winston, J. Perfect, A.J. Ullmann, T.J. Walsh, et al.
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
N Engl J Med, 356 (2007), pp. 348-359
[57.]
J.P. Burnie, T.L. Carter, S.J. Hodgetts, R.C. Matthews.
Fungal heat-shock proteins in human disease.
FEMS Microbiol Rev, 30 (2006), pp. 53-88
[58.]
J. Pachl, P. Svoboda, F. Jacobs, K. Vandewoude, H.B. van der, P. Spronk, et al.
A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis.
Clin Infect Dis, 42 (2006), pp. 1404-1413
[59.]
R. Herbrecht, C. Fohrer, Y. Nivoix.
Mycograb for the treatment of invasive candidiasis.
Clin Infect Dis, 43 (2006), pp. 1083-1084
[60.]
J.A. Stone, S.D. Holland, P.J. Wickersham, A. Sterrett, M. Schwartz, C. Bonfiglio, et al.
Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.
Antimicrob Agents Chemother, 46 (2002), pp. 739-745
[61.]
J. Hiemenz, P. Cagnoni, D. Simpson, S. Devine, N. Chao, J. Keirns, et al.
Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant.
Antimicrob Agents Chemother, 49 (2005), pp. 1331-1336
[62.]
J.A. Dowell, W. Knebel, T. Ludden, M. Stogniew, D. Krause, T. Henkel.
Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal.
J Clin Pharmacol, 44 (2004), pp. 590-598
[63.]
A. Villanueva, E.G. Arathoon, E. Gotuzzo, R.S. Berman, M.J. DiNubile, C.A. Sable.
A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis.
Clin Infect Dis, 33 (2001), pp. 1529-1535
[64.]
E.G. Arathoon, E. Gotuzzo, L.M. Noriega, R.S. Berman, M.J. DiNubile, C.A. Sable.
Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases.
Antimicrob Agents Chemother, 46 (2002), pp. 451-457
[65.]
A. Villanueva, E. Gotuzzo, E.G. Arathoon, L.M. Noriega, N.A. Kartsonis, R.J. Lupinacci, et al.
A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis.
Am J Med, 113 (2002), pp. 294-299
[66.]
N. de Wet, A. Llanos-Cuentas, J. Suleiman, E. Baraldi, E.F. Krantz, N.M. Della, et al.
A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients.
Clin Infect Dis, 39 (2004), pp. 842-849
[67.]
N.T. de Wet, A.J. Bester, J.J. Viljoen, F. Filho, J.M. Suleiman, E. Ticona, et al.
A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis.
Aliment Pharmacol Ther, 21 (2005), pp. 899-907
[68.]
A.C. Reboli, C. Rotstein, P.G. Pappas, S.W. Chapman, D.H. Kett, D. Kumar, et al.
Anidulafungin versus fluconazole for invasive candidiasis.
N Engl J Med, 356 (2007), pp. 2472-2482
Copyright © 2008. Elsevier España S.L.. Todos los derechos reservados
